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Candida biofilms are a major cause of nosocomial morbidity and mortality. The mech-
anism by which Candida biofilms evade the immune system remains unknown. In this 
perspective, we develop a theoretical framework of the three, not mutually exclusive, 
models, which could explain biofilm evasion of host immunity. First, biofilms may exhibit 
properties of immunological silence, preventing immune activation. Second, biofilms 
may produce immune-deviating factors, converting effective immunity into ineffective 
immunity. Third, biofilms may resist host immunity, which would otherwise be effective. 
Using a murine subcutaneous biofilm model, we found that mice infected with biofilms 
developed sterilizing immunity effective when challenged with yeast form Candida. 
Despite the induction of effective anti-Candida immunity, no spontaneous clearance 
of the biofilm was observed. These results support the immune resistance model of 
biofilm immune evasion and demonstrate an asymmetric relationship between the host 
and biofilms, with biofilms eliciting effective immune responses yet being resistant to 
immunological clearance.
Keywords: biofilms, Candida, cytokines, trained immunity, immune resistance
iNtrODUctiON
Candida albicans can exist in both a unicellular yeast form and a colonial biofilm form. The majority 
of diseases caused by C. albicans include the formation of such a biofilm (1–4). Biofilms shield the 
fungi from environmental factors and are associated with poor immune clearance by the host (5). 
C. albicans can potentially form biofilm on all implanted medical devices (6, 7), and, as the host 
immune system appears incapable of eradicating biofilms, removal of the devices is often required 
(8). In addition, C. albicans can also form biofilms in mucosal surfaces such as the vaginal cavity 
(vulvovaginal candidiasis). These infections are typically not spontaneously cleared by the immune 
system and usually require antifungals (9–11). Immune evasion of Candida biofilms therefore incurs 
a large public health burden and socioeconomic costs.
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Host clearance Mechanisms of Yeast 
Form Candida infections
Being a commensal, C. albicans has a remarkable capacity of 
adaptation to different niches within its host. However, despite 
the near ubiquity of commensal Candida, invasive infection by 
yeast form is rare. The immunological response that normally 
maintains C. albicans as a commensal rather than a pathogen 
is coordinated by Th17  cells (Figure  1A). The Th17 basis of 
immunity is revealed through the study of congenital forms of 
Candida susceptibility, which, despite representing only a tiny 
fraction of Candida infections, inform as to the immunological 
pathways essential for preventing infection. Evidence of Th17 
involvement in anti-Candida host defense comes from a diverse 
group of patients. Patients with deficiencies in the autoimmune 
regulator gene (AIRE) present with an autosomal recessive syn-
drome called autoimmune polyendocrinopathy syndrome type 
1 (APS1), of which chronic mucocutaneous candidiasis (CMC) 
is a key feature. A subset of patients with APS1 has high titers 
of neutralizing autoantibodies against IL-17A, IL-17F, and IL-22, 
but not against other cytokines, which correlates with the subset 
of patients that develop CMC (12, 13). Furthermore, Puel et al. 
described a loss of function mutation in the IL-17RA, which 
causes an inability to signal in response to IL-17A and IL-17F, 
creating a Th17 deficiency and a susceptibility to CMC (14). In 
addition to the requirement for an effective Th17 response, man-
nose-binding lectin (MBL) is important for controlling Candida 
infections. MBL deficiencies are associated with susceptibility to 
Candida infections, where deficient patients with lower circulat-
ing levels of MBL are susceptible to fungal infections, such as 
Candida vaginitis (15). In the presence of healthy MBL and Th17 
levels, fulminant infection with the yeast form of C. albicans is 
rare, indicating the effectiveness of this immunological pathway.
A theoretical Framework for 
Understanding Host immune evasion by 
Candida Biofilms
As the majority of infections caused by C. albicans are associated 
with biofilm formation, it is critical to understand the interaction 
between the host immune system and C. albicans biofilms. While 
the yeast form of C. albicans is rapidly cleared from healthy indi-
viduals, once a biofilm has developed (e.g., during vulvovaginal 
candidiasis or on implanted medical devices), it is capable of 
long-term evasion of host immunity. Here, we propose three 
basic models that are each capable of explaining the phenomenon 
of host immunity evasion by Candida biofilms. These models are 
not mutually exclusive and together cover the majority of mecha-
nistic scenarios that are hypothetically capable of explaining the 
observed evasion.
The first theoretical model for host immune evasion is that 
of immunological silence (Figure 1B). This model was proposed 
by Nett and colleagues to explain the paucity of infiltrating 
leukocytes into the biofilm site (16, 17). This model covers a 
diverse set of potential scenarios in which the Candida biofilm 
remains “hidden” from the host immune system, with a failure to 
activate host anti-Candida pathways. A definitive example of such 
a mechanism would be shielding of the biofilm by the biofilm 
matrix, preventing the release of pathogen-associated molecular 
patterns and microbial antigens. Such as shielding would ensure 
that the host immune system remained ignorant of biofilm pres-
ence. A potential difficulty of the immunological silence models 
is the clinical observation of concurrent biofilm and commensal 
colonizations. As the latter is actively controlled by host immunity, 
a model relying on immunological silence must include a proviso 
that the silence only needs to be local in scope, rather than global, 
with the activation of effective immunity by commensals unable 
to extend to the site of biofilm infection.
The second theoretical model capable of explaining biofilm 
evasion of host immunity is that of immune deviation (Figure 1C). 
Netea and colleagues have proposed a model whereby the biofilm 
is capable of producing factors that deviate the immune response 
into an ineffective format (18, 19). In principle, such factors could 
directly (i.e., a direct impact on leukocytes) or indirectly (e.g., 
induce the production of host immunomodulatory factors) drive 
immune deviation. This model is supported by the observation 
that C. albicans cell wall components can induce IL-10 expression 
(18, 19), known to be effective at supporting Th2 responses at the 
expense of Th17 responses (20). In this scenario, anti-Candida 
T  cells would be activated; however, the deviation into a Th2 
response would result in an ineffective immune response, allow-
ing the biofilm to evade clearance.
The third theoretical model to explain long-term survival of the 
biofilm in the host is that of immune resistance (Figure 1D). This 
model needs to invoke neither immune silence nor immune devia-
tion, i.e., it is capable of explaining biofilm immune evasion even in 
the presence of a biofilm-induced effective anti-Candida response. 
Instead, this model postulates that the structural–mechanical 
or molecular features of the biofilm may render the biofilm- 
associated Candida resistant to immune clearance. Mechanisms 
such as immune exclusion from the biofilm or a cellular resistance 
to toxic immune mediators would be covered under this model. 
This immune resistance model is analogous to the role of the bio-
film matrix in Candida resistance to antifungal drugs (19, 21, 22).
Despite the sharp theoretical division between these models, 
existing data are still compatible with each model. For example, 
the paucity of infiltrating leukocytes in the Candida biofilm (16) 
could be due to either immune silence, preventing immune trig-
gering and thus relying on passive exclusion, immune deviation, 
producing an abnormal immune response which does not result 
in infiltration, or immune resistance, where the immune system 
is triggered but actively excluded from the site. While data do 
not exist for a definitive selection of the correct model, division 
of potential mechanisms into these three models provides a 
theoretical framework to design those experiments capable of 
distinguishing between them.
empirical testing of Candida Biofilm 
evasion Models supports immunological 
resistance As the Dominant Mechanism
Having developed a theoretical framework for the mechanisms by 
which Candida biofilms may evade clearance by the host immune 
system, we sought to formally distinguish between these possible 
modalities of host–pathogen relationships. Several mouse models 
FigUre 1 | continued
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FigUre 1 | A theoretical framework for understanding Candida biofilm immune evasion. (A) In a healthy host, infection with the yeast form of Candida albicans 
causes pathogen-associated molecular pattern (PAMPs) release and drives the induction of Th17 cells. Th17 cells, in turn, coordinate an effective host anti-
pathogen response, clearing the infection. This process is seemingly inoperative in a Candida biofilm growth, for unknown reasons. (B) The first model capable of 
explaining the immune evasion of C. albicans biofilms is one of immunological silence. In this model, biofilm structure prevents the release of PAMPs and thereby 
prevents the initiation of T cell activation and polarization into the effective Th17 lineage. (c) The second model to potentially explain biofilm immune evasion is that 
of immunological deviation. In this model, while the biofilm causes the release of PAMPs and thus the activation of a T cell response against C. albicans, additional 
factors are produced which deviate the responding T cells from an effective Th17 program into an ineffective (e.g., Th2) program. The resulting host immunity is 
therefore unable to clear the infection. (D) The final model capable of explaining the persistence of C. albicans biofilms is that of immune resistance. In this model, 
even in cases where an effective Th17 anti-Candida response is initiated, the biofilm remains resistant to the host immunity (e.g., exclusion of effector cells from the 
biofilm).
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have been developed to study Candida biofilms in vivo, typically 
utilizing immunosuppression (23, 24). As exogenous immunosup-
pression would prevent the utility of such a model for studying 
immune evasion, we developed a mouse model of C. albicans 
biofilm growth, which does not rely on immune suppression. C. 
albicans biofilms were grown on subcutaneous catheter pieces and 
implanted into both immunocompetent (IC) and dexamethasone-
treated (DEX) mice, using the dose of dexamethasone required 
for previous immunosuppression-dependent models (Figure 2A). 
No major difference in the number of viable Candida recoverable 
from the biofilm was observed between the IC and DEX mice 
(Figure 2B), indicating a limited capacity of the immune system 
to clear biofilm infections within the 6-day window of observa-
tion. Furthermore, biofilm growth occurred in the first 4  days 
following implantation, with stable maintenance of viable Candida 
recoverable to at least 15 days postimplantation (Figure 2C). The 
maintained C. albicans biomass formed classical biofilms, visible 
by scanning electron microscopy (Figure 2D) and confocal laser 
scanning microscopy (Figure 2E). Despite the kidneys being the 
main infected organs in a systemic infection model, no colony-
forming units (CFUs) were detected in kidneys of implanted mice 
(data not shown), indicating that C. albicans, when present in a 
biofilm on a subcutaneous catheter, does not release yeast form 
Candida capable of infecting distant organs. Together, the forma-
tion and robust maintenance of subcutaneous C. albicans biofilms 
in IC C57Bl/6 mice is consistent with the failure of the host immune 
system to eradicate biofilms in patients and provides a system for 
mechanistically testing the hypothesis of immune resistance of the 
biofilm without the limitations inherent to patient study.
We next developed an experimental setup capable of formally 
distinguishing the immune resistance model from the models of 
immune silence or deviation. It has been previously shown that 
a low intravenous (i.v.) exposure to yeast form C. albicans can 
protect mice from a subsequent lethal high-dose challenge (25). 
When these data are considered in our theoretical framework of 
immune evasion models, it provides an avenue for formal test-
ing. The models of biofilm immune silence or immune deviation 
would postulate that C. albicans biofilms would either gener-
ate no immune response or an ineffective immune response, 
respectively, such that a biofilm exposure would not provide the 
protective effect generated by yeast-form exposure. The model of 
biofilm immunological resistance, by contrast, allows C. albicans 
biofilms to generate high-quality immune responses (which have 
no impact on the biofilm, due to intrinsic resistance mechanisms), 
which would nonetheless be capable of protection against a lethal 
yeast-form challenge.
We therefore designed an immunization experiment to test the 
capacity of the C. albicans biofilm to induce protective immunity 
against the yeast form and thus distinguish immune resistance 
from immune silence or immune deviation. Mice were either left 
as naïve (implantation of clean catheters to control for surgery), 
implanted with a subcutaneous C. albicans biofilm formed from 
5 × 104 CFU per catheter, or i.v. immunized with 5 × 104 yeast 
form Candida CFU. 14  days after low-dose infection, all mice 
were then challenged i.v. with 107 CFU C. albicans (Figure 3A). 
Based on the three proposed models, it is expected that (i) if 
the biofilm is immunologically silent, mice inoculated with a 
low-dose Candida biofilm would behave like the naïve mice and 
present with a high-death rate; (ii) if the biofilm is presenting with 
immune deviation, mice inoculated with a low-dose Candida 
biofilm, would again behave like naïve mice, and have a similar 
or higher death rate, since the immune response being induced 
is deviated into an ineffective direction; and (iii) in the immune 
resistance model, mice inoculated with a low-dose Candida 
biofilm would behave like the mice inoculated with a low-dose 
i.v. Candida, have a low death rate since the biofilm is triggering 
trained immunity.
Using the biofilm/yeast-form immunization model and by tak-
ing serum samples at baseline, before surgery or i.v. infection, and 
at 7-day intervals, we were able to track the cytokine production 
as the infection progressed (Figures 3B–G). IL-6 and TNFα were 
significantly increased as a consequence of both the low-dose 
infection and the implantation of the catheters (measured at days 
0 and 7) (Figures 3D,E). Following the high-dose challenge on 
day 14, 7 days later (day 21), we saw a significant increase in IFNγ, 
IL-6, and TNFα (Figures 3C–E) for all groups, indicating that 
the systemic inflammation regardless of prior exposure. The key 
immunological readout in this assay is protection from infection. 
Naïve mice were highly susceptible to the high-dose (107) intrave-
nous infection, with 60% of mice dying within 3 days, and ~90% 
dying by 6 days (Figure 3H). By contrast, as previously described, 
mice immunized with a 5 × 104 i.v. Candida demonstrated pro-
tective immunity, with 50% survival out to day 14 (Figure 3H). 
Critically, mice receiving the same dose of C. albicans in a biofilm 
form showed the same protection against a lethal second dose 
in the yeast form (Figure  3H), formally demonstrating that 
C. albicans biofilms generate effective immune responses from 
the host, despite being resistant to the resulting immunity. At the 
level of yeast eradication, the immune response induced by both 
C. albicans biofilms and the low-dose yeast form was effective at 
reducing the infectious load, with sterilizing or near-sterilizing 
immunity in both groups at day 14 post-challenge, compared with 
FigUre 2 | Candida albicans biofilms are robustly maintained in C57BL/6 mice without immunosuppression. (A) Catheter pieces were incubated overnight in 
mouse serum and for 90 min in C. albicans culture at day 0, following by subcutaneous implantation. In the dexamethasone-treated (DEX) group, dexamethasone 
(1 mg/L) was added in the drinking water from day 2 and maintained over the course of the experiment. Biofilm colony-forming units (CFUs) were read out at 
indicated days postimplantation. (B) Log10 of biofilm CFUs compared between immunocompetent (IC) and DEX mice (n = 3) at 2 and 6 days. Mean ± SEM are 
shown. (c) Log10 of biofilm CFUs followed over time (n = 3–6/group), day 0 = before implantation of catheter pieces. Mean and SEM are shown. One-way ANOVA 
with multiple comparisons was used for comparison of the different time points (*p < 0.05). (D) Representative scanning electron microscopy images of 
preimplantation (top), 2 days after implantation (middle), and day 15 after implantation (bottom). (e) Confocal laser scanning microscopy images of catheter pieces 
before implantation (top) and 15 days postimplantation (bottom). Scale bar = 20 µm.
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the infectious load in end-stage naïve mice (Figure 3I). Together, 
these results formally demonstrate that biofilms promote efficient 
immunity in the host, capable of sterilizing immunity, and yet are 
resistant to immune clearance.
cONcLUDiNg reMArKs
The ability of Candida biofilms to evade host immune clearance 
can be explained through three, not mutually exclusive, models. 
These models are (i) immunological silence, with the biofilm 
preventing immune sensing; (ii) immunological deviation, with 
the biofilm driving the immune response into a non-productive 
avenue; and (iii) immune resistance, with the biofilm no longer 
being sensitive to the same immunological attacks competent to 
clear non-biofilm forms. While research in the field often starts 
through identification of molecular pathways and then requires 
elucidation of the mechanism, clustering all potential pathways of 
immune evasion into these three basic models allows the reverse 
approach, where the general mechanism can first be understood, 
driving the identification of molecular pathway.
FigUre 3 | Candida albicans biofilm promotes sterilizing immunity against infection lethal dose of yeast form C. albicans. (A) Mice were surgically implanted with 
sterile catheters (“naïve” group, n = 24), with catheters seeded with 5 × 104 Candida for biofilm growth (“biofilm immunized” group, n = 25) or i.v. injected with 5 × 104 
Candida (“yeast-form immunized” group, n = 25) on day 0. On day 14, each group was challenged with a 107 colony forming unit (CFU) Candida i.v. Mice were 
monitored for cytokine expression on days 0, 7, 14, 21, and 28. (B) Serum samples from all the time points were analyzed for IL-2, (c) IFNγ, (D) IL-6, (e) TNFα,  
(F) muCXCL1, and (g) IL-10. Kruskal–Wallis test was used to compare the different groups at the same time point and to different time points. Average ± SEM.  
(H) Survival of all mice groups post high-dose challenge (1 × 107 CFU). (i) Kidney colonization, showing the average count (Log10 CFU) per mouse on both kidneys 
after high-dose challenge for naïve mice (date of death, n = 12), biofilm immunized mice (n = 10, day 14 post-challenge), and yeast-form immunized mice (n = 12, day 
14 post-challenge). Cytokine and survival data are pooled from two independent experiments (**p < 0.005, ***p < 0.0001, and ****p < 0.00001).
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As proof-of-principle of the utility of this perspective, we 
designed experiments in which the different models proposed 
here would give unique outcomes. Using an animal model of 
Candida infection, we demonstrated that a subcutaneous biofilm 
can confer an immunological memory or trained immunity to 
the host, as evidenced by an increase in survival and the eradica-
tion of yeast from the kidney. This mouse experiment formally 
demonstrates that the biofilm is not immunologically silent, nor 
does it create a systemic immune deviation capable of inhibiting 
anti-Candida responses. Rather, the biofilm’s structure renders 
it unresponsive to immunological challenge, the “immune 
resistance” model. The biofilm structure functions to create 
an asymmetry in the relationship between host and microbe, 
with the immune system able to recognize and respond to the 
infection, but with the biofilm sheltering the pathogen from 
eradication. While our study does not attempt to identify the 
molecular determinants of this immune resistance, it provides 
a framework of the key characteristics on which future research 
can be based.
MAteriALs AND MetHODs
Mice
Animals used for the experiments were 8–10 weeks old female 
C57BL/6J mice bred in-house or purchased from Janvier Labs. 
Food and water were supplied ad  libitum. Immunosuppression 
was carried out by dexamethasone in drinking water at 1 mg/L 
(26). Cytokine serum levels were quantified by an electrochemi-
luminescence immunoassay format using Meso Scale Discovery 
(Rockville, MD, USA) murine pro-inflammatory panel 1.
infection Models
Candida albicans strain SC5314 (27) was used for mouse infec-
tion studies. For growth and quantification details, see below. 
For immunization experiments, C57BL/6J were subcutane-
ously implanted with six clean catheter pieces or six C. albicans 
colonized catheter pieces, or injected intravenously with 5 × 104 
Candida CFU (see Candida albicans Growth and Quantification 
for culturing details). The same Candida preculture was used 
in the latter two and cultured as described for systemic infec-
tion. Day 14 after treatment, all mice received 107 C. albicans. 
Takedown of surviving mice and catheter and kidney explant was 
performed at day 28.
C. albicans growth and Quantification
Candida albicans strain SC5314 (27) was maintained on YPD 
agar plates comprised 1% yeast extract (Merck), 2% bactopep-
tone (Oxoid), 2% glucose (Fluka analytics), and 1.5% Difco agar 
(BD). To quantify C. albicans biomass in kidneys, the kidneys 
were removed aseptically and homogenized (PRO250) in PBS. 
To quantify C. albicans biomass on catheter pieces, aseptically 
explanted catheter pieces were stored in 1× PBS, sonicated for 
10 min at 40 kHz, and vortexed for 30 s. For each sample type, 
serial dilutions were made in PBS and plated in duplicate on YPD 
agar plates with 50 mg/L chloramphenicol. Plates were incubated 
at 37°C for 1–2 days. CFUs were calculated by taking the mean 
of both duplicates of the lowest dilution resulting in a countable 
number of colonies on the plate.
For subcutaneous biofilm infections, polyurethane triple-
lumen intravenous catheters (Arrow International) were cut into 
pieces of 1 cm and incubated overnight in mouse serum (Sigma) at 
37°C. C. albicans cell cultures were grown overnight in YPD liquid 
medium at 37°C, counted using a Bürker Chamber (Labor Optik), 
and the desired challenge inocula were prepared in RPMI-1640 
medium (Sigma-Aldrich) buffered at pH 7.0 with 34.53 g/L MOPS 
(Sigma-Aldrich). Serum-coated catheter pieces were incubated for 
90 min in 1 mL of cell suspension or in 1 mL of RPMI-MOPS. After 
incubation, catheter pieces were washed twice with PBS before 
being implanted. Surgery and explant of the catheter pieces was 
performed as described before (26, 28). Animals were anesthetized 
by injecting a cocktail of 45–60 mg/kg ketamine (Anesketin®) and 
0.6–0.8  mg/kg medetomidine (Domitor®) in sterile saline i.p. 
Anesthesia was reversed by i.p. injection of 0.5 mg/kg atipamezole 
(Antisedan®) in sterile saline (28).
For systemic infection, a single C. albicans colony from a YPD 
agar plate was incubated at 30°C for 24 h was restreaked on a fresh 
YPD agar plate and grown at 30°C for another 24 h. A single colony 
from the latter was incubated in liquid YPD medium and grown 
for 12–14 h at 30°C shaking at 200 rpm. Cells were counted using 
the Bürker chamber; the desired inocula were prepared in a sterile 
saline solution and confirmed by plating. Mice were infected or 
mock infected (PBS) by injection in the lateral tail vein.
Microscopy
Microscopy was modified from published protocols (26). Briefly, 
catheter pieces were cut longitudinally opening up the lumen 
and were allowed to air dry overnight. For scanning electron 
microscopy, mounted samples were sputter coated with Au–Pd 
and examined on an FEI XL30-FEG at 10 kV and 10 mm working 
distance. For confocal laser scanning microscopy, catheter pieces 
were cut longitudinally and stained using a 1/1,000 dilution of 
Alexa488-Concanavalin A in PBS. Samples were examined using 
an Olympus Fluoview FV1000 IX81.
statistics
All the groups were compared using Kruskal–Wallis test with 
a Dunn correction, or one-way ANOVA where stated. Survival 
curves were analyzed by Mantel–Cox test. Statistical analyses 
were performed using GraphPad Prism 6.04.
etHics stAteMeNt
All animal experiments were carried out by competent researches 
under the laboratory license LA1210570 and protocol number 
P122/2013, which was reviewed and approved by the KU Leuven ani-
mal ethical committee. Animal experiments adhered to the Belgian 
Royal Decree and the European Directive 2010/63/EU regulations 
regarding the protection and well-being of laboratory animals. All 
animal experiments were designed with the 3Rs guidelines.
AUtHOr cONtriBUtiONs
Methodology and resources: JG-P, LM, SH-B, and AB. Validation, 
formal analysis, investigation, and writing-original draft: JG-P and 
LM. Writing review and editing: JG-P, LM, and AL. Supervision, 
project administration, and funding acquisition: AL, PD, and KL.
8Garcia-Perez et al. Evasion of Host Immunity by Candida Biofilms
Frontiers in Immunology | www.frontiersin.org March 2018 | Volume 9 | Article 538
reFereNces
1. Nett J, Andes D. Candida albicans biofilm development, modeling a 
host-pathogen interaction. Curr Opin Microbiol (2006) 9:340–5. doi:10.1016/ 
j.mib.2006.06.007 
2. Tsui C, Kong EF, Jabra-Rizk MA. Pathogenesis of Candida albicans biofilm. 
Pathog Dis (2016) 74:ftw018. doi:10.1093/femspd/ftw018 
3. Mathé L, Van Dijck P. Recent insights into Candida albicans biofilm resis-
tance mechanisms. Curr Genet (2013) 59:251–64. doi:10.1007/s00294-013- 
0400-3 
4. Peng S, Lu Y. Clinical epidemiology of central venous catheter-related 
bloodstream infections in an intensive care unit in China. J Crit Care (2013) 
28:277–83. doi:10.1016/j.jcrc.2012.09.007 
5. Ramage G, Williams C. The clinical importance of fungal biofilms. Adv Appl 
Microbiol (2013) 84:27–83. doi:10.1016/B978-0-12-407673-0.00002-3 
6. Donlan RM. Biofilms and device-associated infections. Emerg Infect Dis 
(2001) 7:277–81. doi:10.3201/eid0702.700277 
7. Ramage G, Martínez JP, López-Ribot JL. Candida biofilms on implanted bio-
materials: a clinically significant problem. FEMS Yeast Res (2006) 6(7):979–86. 
doi:10.1111/j.1567-1364.2006.00117.x 
8. Koehler P, Tacke D, Cornely OA. Our 2014 approach to candidaemia. Mycoses 
(2014) 57:581–3. doi:10.1111/myc.12207 
9. Harriott MM, Lilly EA, Rodriguez TE, Fidel PL, Noverr MC. Candida albicans 
forms biofilms on the vaginal mucosa. Microbiology (2010) 156:3635–44. 
doi:10.1099/mic.0.039354-0 
10. Gonçalves B, Ferreira C, Alves CT, Henriques M, Azeredo J, Silva S. 
Vulvovaginal candidiasis: epidemiology, microbiology and risk factors. Crit 
Rev Microbiol (2015) 7828:1–23. doi:10.3109/1040841X.2015.1091805 
11. Pappas PG, Rex JH, Sobel JD, Filler SG, Dismukes WE, Walsh TJ, et  al. 
Guidelines for treatment of candidiasis. Clin Infect Dis (2004) 38:161–89. 
doi:10.1097/01.idc.0000130888.27859.52 
12. Kisand K, Bøe Wolff AS, Podkrajsek KT, Tserel L, Link M, Kisand KV, et al. 
Chronic mucocutaneous candidiasis in APECED or thymoma patients cor-
relates with autoimmunity to Th17-associated cytokines. J Exp Med (2010) 
207:299–308. doi:10.1084/jem.20091669 
13. Puel A, Döffinger R, Natividad A, Chrabieh M, Barcenas-Morales G, Picard C, 
et al. Autoantibodies against IL-17A, IL-17F, and IL-22 in patients with chronic 
mucocutaneous candidiasis and autoimmune polyendocrine syndrome type I. 
J Exp Med (2010) 207:291–7. doi:10.1084/jem.20091983 
14. Puel A, Picard C, Cypowyj S, Lilic D, Abel L, Casanova JL. Inborn errors of 
mucocutaneous immunity to Candida albicans in humans: a role for IL-17 
cytokines? Curr Opin Immunol (2010) 22:467–74. doi:10.1016/j.coi.2010. 
06.009 
15. Damiens S, Poissy J, François N, Salleron J, Jawhara S, Jouault T, et al. Mannose-
binding lectin levels and variation during invasive candidiasis. J Clin Immunol 
(2012) 32:1317–23. doi:10.1007/s10875-012-9748-2 
16. Johnson CJ, Cabezas-Olcoz J, Kernien JF, Wang SX, Beebe DJ, Huttenlocher 
A, et  al. The extracellular matrix of Candida albicans biofilms impairs for-
mation of neutrophil extracellular traps. PLoS Pathog (2016) 12:e1005884. 
doi:10.1371/journal.ppat.1005884 
17. Nett JE. The host’s reply to Candida biofilm. Pathogens (2016) 5:33. doi:10.3390/
pathogens5010033 
18. Netea MG, Joosten LA, van der Meer JW, Kullberg BJ, van de Veerdonk FL. 
Immune defence against Candida fungal infections. Nat Rev Immunol (2015) 
15:630–42. doi:10.1038/nri3897 
19. Netea MG, Brown GD, Kullberg BJ, Gow NAR. An integrated model of 
the recognition of Candida albicans by the innate immune system. Nat Rev 
Microbiol (2008) 6:67–78. doi:10.1038/nrmicro1815 
20. Chaudhry A, Samstein RM, Treuting P, Liang Y, Pils MC, Heinrich JM, et al. 
Interleukin-10 signaling in regulatory T cells is required for suppression of 
Th17 cell-mediated inflammation. Immunity (2011) 34:566–78. doi:10.1016/ 
j.immuni.2011.03.018 
21. Mitchell KF, Zarnowski R, Sanchez H, Edward JA, Reinicke EL, Nett JE, et al. 
Community participation in biofilm matrix assembly and function. Proc Natl 
Acad Sci U S A (2015) 112:4092–7. doi:10.1073/pnas.1421437112 
22. Nett JE, Sanchez H, Cain MT, Andes DR. Genetic basis of Candida biofilm 
resistance due to drug-sequestering matrix glucan. J Infect Dis (2010) 
202:171–5. doi:10.1086/651200 
23. Coenye T, Nelis HJ. In vitro and in  vivo model systems to study microbial 
biofilm formation. J Microbiol Methods (2010) 83:89–105. doi:10.1016/ 
j.mimet.2010.08.018 
24. Tournu H, Van Dijck P. Candida biofilms and the host: models and new concepts 
for eradication. Int J Microbiol (2012) 2012:845352. doi:10.1155/2012/845352 
25. Quintin J, Saeed S, Martens JHA, Giamarellos-Bourboulis EJ, Ifrim DC, Logie 
C, et al. Candida albicans infection affords protection against reinfection via 
functional reprogramming of monocytes. Cell Host Microbe (2012) 12:223–32. 
doi:10.1016/j.chom.2012.06.006 
26. Ricicová M, Kucharíková S, Tournu H, Hendrix J, Bujdáková H, Van Eldere 
J, et  al. Candida albicans biofilm formation in a new in  vivo rat model. 
Microbiology (2010) 156:909–19. doi:10.1099/mic.0.033530-0 
27. Gillum AM, Tsay EYH, Kirsch DR. Isolation of the Candida albicans gene 
for orotidine-5′-phosphate decarboxylase by complementation of S. cere-
visiae ura3 and E. coli pyrF mutations. Mol Gen Genet (1984) 198:179–82. 
doi:10.1007/BF00328721 
28. Kucharíková S, Vande Velde G, Himmelreich U, Van Dijck P. Candida albi-
cans biofilm development on medically-relevant foreign bodies in a mouse 
subcutaneous model followed by bioluminescence imaging. J Vis Exp (2015) 
95:52239. doi:10.3791/52239 
Conflict of Interest Statement: The authors declare that the research was con-
ducted in the absence of any commercial or financial relationships that could be 
construed as a potential conflict of interest.
Copyright © 2018 Garcia-Perez, Mathé, Humblet-Baron, Braem, Lagrou, Van Dijck 
and Liston. This is an open-access article distributed under the terms of the Creative 
Commons Attribution License (CC BY). The use, distribution or reproduction in 
other forums is permitted, provided the original author(s) and the copyright owner 
are credited and that the original publication in this journal is cited, in accordance 
with accepted academic practice. No use, distribution or reproduction is permitted 
which does not comply with these terms.
AcKNOWLeDgMeNts
The authors thank Diana Pombal, Kim Staats, James Dooley, 
Celia Lobo-Romero, Cindy Colombo, Ilse Palmans, and Sona 
Kucharíková for technical assistance.
FUNDiNg
This study was supported by a KU Leuven Interdisciplinary 
Research Project (Project IDO/11/005 3E120220) and by the 
FWO biofilm research community (WO.009.16N).
